1 Mancinelli R, "Vasopressin regulates the growth of the biliary epithelium in polycystic liver disease" 96 : 1147-1155, 2016
2 Torres VE, "Tolvaptan in patients with autosomal dominant polycystic kidney disease" 367 : 2407-2418, 2012
3 Mizuno H, "Tolvaptan for the treatment of enlarged polycystic liver disease" 7 : 108-111, 2017
4 Onori P, "Role of follicle-stimulating hormone on biliary cyst growth in autosomal dominant polycystic kidney disease" 33 : 914-925, 2013
5 Arnold HL, "New advances in evaluation and management of patients with polycystic liver disease" 100 : 2569-2582, 2005
6 Muto S, "Long-term safety profile of tolvaptan in autosomal dominant polycystic kidney disease patients : TEMPO extension Japan trial" 9 : 93-104, 2017
7 van Keimpema L, "Lanreotide reduces the volume of polycystic liver : a randomized, double-blind, placebo-controlled trial" 137 : 1661-1668.e1-e2, 2009
8 Slizgi JR, "Inhibition of human hepatic bile acid transporters by tolvaptan and metabolites : contributing factors to drug-induced liver injury?" 149 : 237-250, 2016
9 Masyuk AI, "Cholangiocyte autophagy contributes to hepatic cystogenesis in polycystic liver disease and represents a potential therapeutic target" 67 : 1088-1108, 2018
10 Torres VE, "Angiotensin blockade in late autosomal dominant polycystic kidney disease" 371 : 2267-2276, 2014
1 Mancinelli R, "Vasopressin regulates the growth of the biliary epithelium in polycystic liver disease" 96 : 1147-1155, 2016
2 Torres VE, "Tolvaptan in patients with autosomal dominant polycystic kidney disease" 367 : 2407-2418, 2012
3 Mizuno H, "Tolvaptan for the treatment of enlarged polycystic liver disease" 7 : 108-111, 2017
4 Onori P, "Role of follicle-stimulating hormone on biliary cyst growth in autosomal dominant polycystic kidney disease" 33 : 914-925, 2013
5 Arnold HL, "New advances in evaluation and management of patients with polycystic liver disease" 100 : 2569-2582, 2005
6 Muto S, "Long-term safety profile of tolvaptan in autosomal dominant polycystic kidney disease patients : TEMPO extension Japan trial" 9 : 93-104, 2017
7 van Keimpema L, "Lanreotide reduces the volume of polycystic liver : a randomized, double-blind, placebo-controlled trial" 137 : 1661-1668.e1-e2, 2009
8 Slizgi JR, "Inhibition of human hepatic bile acid transporters by tolvaptan and metabolites : contributing factors to drug-induced liver injury?" 149 : 237-250, 2016
9 Masyuk AI, "Cholangiocyte autophagy contributes to hepatic cystogenesis in polycystic liver disease and represents a potential therapeutic target" 67 : 1088-1108, 2018
10 Torres VE, "Angiotensin blockade in late autosomal dominant polycystic kidney disease" 371 : 2267-2276, 2014
11 Nakanuma Y, "Adult polycystic liver presenting with progressive hepatic failure" 11 : 592-594, 1989
12 Spirli C, "Adenylyl cyclase 5 links changes in calcium homeostasis to cAMP-dependent cyst growth in polycystic liver disease" 66 : 571-580, 2017
국립중앙도서관 "우편 복사 서비스"로 연결 됩니다.
KCI
KISS
